Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

gavocabtagene autoleucel (TC-210)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Adaptimmune

Drug class:

T-cell stimulant, Mesothelin inhibitor

Related drugs:

‹

BAY 2287411 (0)

naptumomab estafenatox (0)

CD30 biAb-AATC (0)

NEO_PLIN2101 (0)

darleukin/fibromun (0)

TAC100-HER2 (0)

TCRT-ESO-A2 (0)

tabelecleucel (0)

UMG2-CD3 BTCE (0)

FH-TCR-Tᴍsʟɴ (0)

anti-Mesothelin CAR NK Cells (0)

autologous redirected RNA meso-CIR T cells (0)

JNJ-64041757 (0)

BAY 2287411 (0)

›

MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Lung Cancer	MSLN expression	Lung Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Ovarian Cancer	MSLN expression	Ovarian Cancer	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN expression	Mesothelioma	MSLN expression	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN overexpression	Ovarian Cancer	MSLN overexpression	Ovarian Cancer	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression	Malignant Pleural Mesothelioma	MSLN overexpression	Malignant Pleural Mesothelioma	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
MSLN overexpression + TP53 mutation	Ovarian Cancer	MSLN overexpression + TP53 mutation	Ovarian Cancer	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4	TC-210 Sensitive: C4 – Case Studies TC-210 Sensitive : C4